Products & Services · Total revenues
ONPATTRO — Total revenues
Alnylam Pharmaceuticals ONPATTRO — Total revenues decreased by 35.4% to $20.48M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 58.6%, from $49.49M to $20.48M. Over 4 years (FY 2021 to FY 2025), ONPATTRO — Total revenues shows a downward trend with a -22.3% CAGR.
Analysis
Metric ID:
alny_segment_onpattro_total_revenuesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $113.84M | $120.32M | $138.63M | $137.01M | $153.43M | $144.95M | $122.22M | $102.49M | $91.46M | $81.59M | $79.01M | $69.22M | $77.24M | $50.29M | $56.1M | $49.49M | $52.54M | $39.08M | $31.69M | $20.48M |
| QoQ Change | — | +5.7% | +15.2% | -1.2% | +12.0% | -5.5% | -15.7% | -16.1% | -10.8% | -10.8% | -3.2% | -12.4% | +11.6% | -34.9% | +11.6% | -11.8% | +6.2% | -25.6% | -18.9% | -35.4% |
| YoY Change | — | — | — | — | +34.8% | +20.5% | -11.8% | -25.2% | -40.4% | -43.7% | -35.4% | -32.5% | -15.5% | -38.4% | -29.0% | -28.5% | -32.0% | -22.3% | -43.5% | -58.6% |
Range$20.48M – $153.43M
CAGR-30.3%
Avg YoY Growth-25.1%
Median YoY Growth-30.5%
Current Streak3 quarters decline
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's onpattro — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported onpattro — total revenues of $20.48M in Q1 2026.
- How has Alnylam Pharmaceuticals's onpattro — total revenues changed year-over-year?
- Alnylam Pharmaceuticals's onpattro — total revenues decreased by 58.6% year-over-year, from $49.49M to $20.48M.
- What is the long-term trend for Alnylam Pharmaceuticals's onpattro — total revenues?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's onpattro — total revenues has grown at a -22.3% compound annual growth rate (CAGR), from $474.74M to $172.79M.